tiprankstipranks
Trending News
More News >
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
US Market
Advertisement

Praxis Precision Medicines (PRAX) AI Stock Analysis

Compare
648 Followers

Top Page

PRAX

Praxis Precision Medicines

(NASDAQ:PRAX)

Rating:47Neutral
Price Target:
$48.00
▲(6.81% Upside)
Praxis Precision Medicines faces significant financial challenges, with ongoing net losses and negative cash flows being the most critical factors affecting its stock score. Despite these financial difficulties, the company has shown promising clinical developments and received positive regulatory feedback, which provides some optimism for future growth. Technical indicators and valuation metrics are currently unfavorable, further weighing down the overall score.
Positive Factors
Efficacy and Competitive Profile
Clinical data suggests that both vormatrigine and relutrigine have competitive drug profiles in their respective epilepsy treatments.
Market Potential
The analyst raised the price target for the stock to $115, reflecting increased confidence in vormatrigine's market potential and peak sales estimates.
Seizure Reduction Efficacy
PRAX announced very positive Ph2 open-label RADIANT data of vormatrigine in FOS patients, showing a 56.3% median reduction in seizure frequency, with rapid responses seen as early as week 1 and sustained out to week 8.
Negative Factors
Discontinuation Rate
The discontinuation rate of 23% was higher than expected, which is pressuring Praxis shares despite impressive efficacy.
Safety Concerns
Safety looked comparable to competition with 23% discontinuations, which put pressure on PRAX.
Share Pressure
The discontinuation rate of 23% was higher than expected, which is pressuring Praxis shares despite impressive efficacy.

Praxis Precision Medicines (PRAX) vs. SPDR S&P 500 ETF (SPY)

Praxis Precision Medicines Business Overview & Revenue Model

Company DescriptionPraxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
How the Company Makes MoneyPraxis Precision Medicines primarily generates revenue through the development and commercialization of its pipeline of CNS disorder therapies. The company invests in research and development to advance its drug candidates through clinical trials, seeking regulatory approval to bring these therapies to market. Revenue is expected to be generated from product sales, once these therapies are approved, as well as through potential partnerships and collaborations with other pharmaceutical companies. Praxis may also receive milestone payments and royalties from licensing agreements with partners who wish to commercialize its therapies in specific markets.

Praxis Precision Medicines Earnings Call Summary

Earnings Call Date:Aug 04, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant advancements in the efficacy of vormatrigine, strong execution of clinical trials, and a robust financial position. However, challenges remain in managing discontinuation rates and background therapy interactions.
Q2-2025 Updates
Positive Updates
Vormatrigine Best-in-Disease Efficacy
The RADIANT study showed vormatrigine delivered a median seizure reduction of over 56%, with 60% of patients achieving at least a 50% reduction in seizures. Over 22% of patients were completely seizure-free during the second month of treatment.
Strong Patient Recruitment and Study Execution
Praxis successfully exceeded its enrollment target for the RADIANT study, recruiting a larger group of patients than initially planned, demonstrating effective recruitment capabilities.
Positive Mood Impact
Patients in the RADIANT study reported positive impacts on mood, leading to the inclusion of depression and mood endpoints in the POWER2 study design.
Strong Financial Position
Praxis' cash runway extends into 2028, supporting its ambitious clinical agenda.
Negative Updates
23% Discontinuation Rate
The RADIANT study observed a 23% discontinuation rate, linked to lack of background ASM dose adjustment, although it was indicated that this could be managed with appropriate therapy management.
Background Therapy Challenges
There is a need for more proactive dose reduction of background ASMs, as many patients are on toxic concentrations, contributing to adverse events.
Company Guidance
During the Praxis Precision Medicine's conference call, significant guidance was provided on the company's ongoing and future clinical developments. Praxis highlighted the promising results from their RADIANT study of vormatrigine, which showed a median seizure reduction of over 56%, with 60% of patients achieving at least a 50% reduction in seizures. Notably, 22% of patients were seizure-free during the second month of treatment. The company discussed its robust pipeline, featuring four late-stage assets and five expected clinical readouts within the next year. They emphasized their solid financial position, with a cash runway extending into 2028, supporting their ambitious clinical agenda. Looking ahead, Praxis plans to initiate the POWER2 study, which will test vormatrigine doses of 20, 30, and 40 milligrams, and the POWER3 study, aiming to establish vormatrigine as a stand-alone therapy. The company also announced that the full RADIANT study results would be further detailed at upcoming epilepsy conferences.

Praxis Precision Medicines Financial Statement Overview

Summary
Praxis Precision Medicines is facing significant financial challenges, with substantial net losses and negative cash flows. Despite a strong gross profit margin and low debt levels, the company's operational inefficiencies and declining revenue growth are major concerns. The balance sheet remains stable, but the negative return on equity and worsening free cash flow highlight the need for a strategic reevaluation to improve financial health.
Income Statement
35
Negative
Praxis Precision Medicines shows a declining financial performance. The gross profit margin is relatively high at 98.1% for TTM (Trailing-Twelve-Months), but the company is suffering from significant net losses with a net profit margin of -2617.6%. Revenue has decreased by 5% in the TTM period compared to the previous annual report. Both EBIT and EBITDA margins are deeply negative, reflecting ongoing operational challenges.
Balance Sheet
40
Negative
The balance sheet reveals a relatively stable financial position with a debt-to-equity ratio of 0.0024, indicating low leverage. However, the return on equity is significantly negative at -48.4% due to ongoing losses. The equity ratio stands at 91.8%, suggesting strong equity financing but persistent operational losses are a concern.
Cash Flow
30
Negative
Cash flow analysis highlights ongoing financial challenges. The free cash flow is negative and has worsened by 24.5% compared to the previous year. Operating cash flow to net income ratio is 0.77, indicating cash flow issues. The free cash flow to net income ratio is 0.77, reflecting insufficient cash flow to cover losses.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue7.76M8.55M2.45M0.000.000.00
Gross Profit7.67M8.20M2.45M-1.17M-1.59M-746.00K
EBITDA-266.41M-199.81M-125.94M-212.86M-165.47M-61.08M
Net Income-251.01M-182.82M-123.28M-213.07M-166.88M-61.82M
Balance Sheet
Total Assets452.83M483.11M87.95M115.13M292.75M303.18M
Cash, Cash Equivalents and Short-Term Investments301.27M392.57M81.30M100.49M275.91M296.61M
Total Debt755.00K1.37M2.50M4.50M4.31M763.00K
Total Liabilities48.61M37.66M18.28M39.02M41.94M15.72M
Stockholders Equity404.22M445.45M69.67M76.11M250.81M287.46M
Cash Flow
Free Cash Flow-191.36M-131.76M-111.19M-185.49M-125.60M-52.62M
Operating Cash Flow-191.31M-131.76M-111.14M-185.04M-124.55M-52.62M
Investing Cash Flow5.48M-248.49M38.95M96.89M-140.52M4.00K
Financing Cash Flow198.10M514.32M91.87M10.46M107.59M304.42M

Praxis Precision Medicines Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price44.94
Price Trends
50DMA
49.23
Negative
100DMA
43.76
Positive
200DMA
54.03
Negative
Market Momentum
MACD
-1.05
Positive
RSI
46.32
Neutral
STOCH
30.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRAX, the sentiment is Neutral. The current price of 44.94 is below the 20-day moving average (MA) of 46.78, below the 50-day MA of 49.23, and below the 200-day MA of 54.03, indicating a bearish trend. The MACD of -1.05 indicates Positive momentum. The RSI at 46.32 is Neutral, neither overbought nor oversold. The STOCH value of 30.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRAX.

Praxis Precision Medicines Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
$703.00M473.015.47%
55
Neutral
$1.22B-56.95%14.99%14.42%
55
Neutral
$1.26B222.83%35.62%49.58%
51
Neutral
$7.86B-0.33-41.57%2.23%23.26%-2.03%
47
Neutral
$958.42M-60.98%338.45%-19.64%
46
Neutral
$579.86M-29.22%-2.07%22.52%
45
Neutral
$1.02B-64.40%900.35%70.25%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PRAX
Praxis Precision Medicines
44.94
-15.77
-25.98%
GYRE
Gyre Therapeutics
7.71
-4.65
-37.62%
XNCR
Xencor
8.33
-8.30
-49.91%
NTLA
Intellia Therapeutics
11.40
-9.87
-46.40%
XERS
Xeris Pharmaceuticals
7.92
5.28
200.00%
NUVB
Nuvation Bio
3.15
0.14
4.65%

Praxis Precision Medicines Corporate Events

Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Praxis Announces Positive Results from RADIANT Study
Positive
Aug 4, 2025

On August 4, 2025, Praxis Precision Medicines announced positive topline results from the RADIANT study, which evaluated vormatrigine in patients with focal onset seizures. The study showed a 56.3% median reduction in seizure frequency over eight weeks, with 22% of patients achieving complete seizure reduction in the last 28 days. Vormatrigine was well-tolerated, and additional data will be presented at upcoming conferences. The company also initiated two registrational studies for developmental and epileptic encephalopathies and received FDA Breakthrough Therapy Designation for relutrigine. Financially, Praxis reported a net loss of $71.1 million for the second quarter of 2025, with cash reserves expected to fund operations into 2028.

Product-Related AnnouncementsBusiness Operations and Strategy
Praxis Precision Medicines Gains FDA Breakthrough Designation
Positive
Jul 17, 2025

On July 17, 2025, Praxis Precision Medicines announced that the U.S. FDA granted breakthrough therapy designation for relutrigine, a treatment for pediatric patients with SCN2A and SCN8A developmental and epileptic encephalopathies. This designation, supported by positive Phase 2 EMBOLD study data, allows for expedited development and review, potentially enhancing the company’s market position in neurological therapies.

Executive/Board ChangesShareholder Meetings
Praxis Precision Medicines Holds Annual Stockholders Meeting
Neutral
Jun 27, 2025

On June 26, 2025, Praxis Precision Medicines, Inc. held its Annual Meeting of Stockholders, where key decisions were made. Stockholders elected two Class II directors, ratified the appointment of Ernst & Young LLP as the independent accounting firm, and approved executive compensation on a non-binding basis. These outcomes reflect the company’s ongoing governance and operational strategies, potentially impacting its future direction and stakeholder relations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 26, 2025